IRIS
CANONICA, GIORGIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 68.985
Totale 68.985
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 68.985
Totale 68.985
Salva come PNG Salva come JPEG
Città #
Genova 54.660
Rapallo 5.991
Genoa 4.368
Vado Ligure 3.879
Bordighera 87
Totale 68.985
Salva come PNG Salva come JPEG
Nome #
Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early and late phase reactions after allergen-specific challenge. 172
360 degree perspective on allergic rhinitis management in Italy: A survey of GPs, pharmacists and patients 169
Levocetirizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters. 166
The perception of Obstructive Sleep Apnoea/Hypopnoea Syndrome (OSAHS) among Italian general practitioners 160
Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial. 154
Eligibility for treatment with omalizumab in Italy and Germany 154
A Review of the Evidence from Comparative Studies of Levocetirizine and Desloratadine for the Symptoms of Allergic Rhinitis 151
Administration of a polyvalent mechanical bacterial lysate to elderly patients with COPD: Effects on circulating T, B and NK cells. 150
A three-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients. 150
The administration of a polyvalent mechanical bacterial lysate in elderly patients with COPD results in serological signs of an efficient immune response associated with a reduced number of acute episodes 149
Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials. 147
Galectin-3: An early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months 146
Adhesion molecules in allergy. 144
A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis 142
Genuair® Usability Test: Results of a National Public Survey of the Elderly 142
T cell activation through different membrane structures (T3/Ti, T11, T44) and frequency analysis of proliferating and interleukin-2 producer T lymphocyte precursors in aged individuals. 142
CD40 on adult human airway epithelial cells: expression and proinflammatory effects 141
Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria 141
Nasal immunotherapy to Parietaria: evidence of reduction of local allergic inflammation. 140
Molecular phenotyping and biomarker development: Are we on our way towards targeted therapy for severe asthma? 140
A new tool to assess and monitor the burden of chronic cough on quality of life: Chronic Cough Impact Questionnaire. 140
Mepolizumab in the management of severe eosinophilic asthma in adults: Current evidence and practical experience 140
Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. 139
Functionally relevant decreases in activatory receptor expression on NK cells are associated with pulmonary tuberculosis in vivo and persist after successful treatment. 139
A critical evaluation of Anti-IL-13 and Anti-IL-4 strategies in severe asthma 139
Focus on cat allergen (Fel d 1): immunological and aerodynamic characteristics, modality of airway sensitization and avoidance strategies. 138
Inhibition of adhesion molecules by budesonide on a human epithelial cell line (lung carcinoma) 138
Antiallergic drugs and quality of life. 137
Local Side Effects of Sublingual and Oral Immunotherapy 137
Changed allergy pattern in outpatients 136
Catching allergy by a simple questionnaire 136
The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: the results of a double blind, placebo controlled, multicenter clinical trial 136
Viruses and bacteria in acute asthma exacerbations--a GA² LEN-DARE systematic review. 135
Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. 135
Pharmacovigilance of drug allergy and hypersensitivity using the ENDA-DAHD database and the GALEN platform. The Galenda project. 134
The relationship between allergen immunotherapy and omalizumab for treating asthma 134
Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life 134
New insights into airway remodelling in asthma and its possible modulation. 133
Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA(2) LEN taskforce position paper. 133
Efficacy of desloratadine in persistent allergic rhinitis - a GA²LEN study. 132
The functional connection between oral allergy syndrome and united airways disease assessed by oral challenge. 132
A double-blind, placebo-controlled study on the diagnostic accuracy of an electrodermal test in allergic subjects. 132
60Co therapy as an "allergic breakthrough" in a case of food allergy. 132
Allergic diseases and their impact on quality of life. 131
How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint. 131
Allergen-driven HLA-G expression and secretion in peripheral blood mononuclear cells from allergic rhinitis patients 131
When allergic rhinitis is not only allergic. 131
The asthma-rhinitis association: between the clinical hypothesis and the scientific theory. 130
Clara cell 16 protein in COPD sputum: A marker of small airways damage? 130
Personalized medicine in allergy 130
Continuous versus on demand treatment with cetirizine for allergic rhinitis. 129
Proteomics of bronchial biopsies: galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients. 129
Long-term follow-up of nasal immunotherapy to Parietaria: clinical and local immunological effects. 128
Treatment of exercise-induced asthma, respiratory and allergic disorders in sports and the relationship to doping: Part II of the report from the Joint Task Force of European Respiratory Society (ERS) and European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA(2)LEN 128
Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. 128
A new protocol for specific oral tolerance induction in children with IgE-mediated cow's milk allergy. 128
Biomarkers and severe asthma: a critical appraisal. 128
T cell activation surface markers and autologous mixed lymphocyte reaction do not differ in true and pseudo food allergy. 128
Safety of sublingual immunotherapy with a monomeric allergoid in very young children. 127
Airway remodelling in children: when does it start? 127
Standards for practical allergen-specific immunotherapy. 127
GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma 'epidemic'. 127
Cetirizine reduces ICAM-I on epithelial cells during nasal minimal persistent inflammation in asymptomatic children with mite-allergic asthma. 127
Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: A multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: Advanced Immunological Approach in COPD Exacerbation) 127
SQ grass sublingual allergy immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconjunctivitis 127
An update on the asthma-rhinitis link. 126
The natural history of respiratory allergy: a follow-up study of 99 patients up to 10 years 126
Sublingual and oral immunotherapy. 126
Using the congestion quantifier seven-item test to assess change in patient symptoms and their impact. 126
New insights in sublingual immunotherapy. 126
Sublingual immunotherapy. 126
Preliminary evidence for 'aberrant' expression of the leukocyte integrin LFA-1 (CD11a/CD18) on conjunctival epithelial cells of patients with mite allergy 126
Will sublingual immunotherapy offer benefit for asthma? 126
COPD treatment: Real life and experimental effects on peripheral NK cells, their receptors expression and their IFN-γ secretion. 126
Chronic Urticaria Patient Perspective (CUPP): The First Validated Tool for Assessing Quality of Life in Clinical Practice 126
New perspectives in the treatment of allergic rhinitis and asthma in children 125
Sublingual immunotherapy for allergic rhinitis and conjunctivitis. 125
Anti-IL-5 and IL-5Ra: Efficacy and safety of new therapeutic strategies in severe uncontrolled asthma 125
Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper. 125
Comparison of the colony forming capacities of human T lymphocyte subpopulations. 124
Novel anti-inflammatory effects of the inhaled corticosteroid fluticasone propionate during lung myofibroblastic differentiation. 124
Lower airway inflammation before and after house dust mite nasal challenge: An age and allergen exposure-related phenomenon. 124
Inflammatory and mechanical factors of allergen-induced bronchoconstriction in mild asthma and rhinitis 124
Loratadine treatment of rhinitis due to pollen allergy reduces epithelial ICAM-1 expression. 124
Evidence of desloratadine syrup efficacy and tolerability in children with pollen-induced allergic rhinitis. 124
Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. 124
Asthma management in a specialist setting: Results of an Italian Respiratory Society survey 124
Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients. 124
Abnormalities of circulating T cell subsets in atopy: influence of specific immunotherapy. 124
Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper 123
Mechanisms of virus-induced asthma exacerbations: state-of-the-art. A GA2LEN and InterAirways document 123
Levocetirizine in persistent allergic rhinitis: continuous or on-demand use? A pilot study. 123
Why do doctors and patients not follow guidelines? 123
Aerobiologic particle sampling by a new personal collector (Partrap FA52) in comparison to the Hirst (Burkard) sampler. 123
Illness perception, mood and coping strategies in allergic rhinitis: are there differences among ARIA classes of severity? 123
Receptors for immunoglobulins on resting and activated human T cells. 123
CD4+CD25highCD127- regulatory T-cells in COPD: Smoke and drugs effect 123
A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). 122
Nonsteroidal antiallergic treatments in allergic rhinitis. 122
The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy. 122
Totale 13.300
Salva come PNG Salva come JPEG
Categoria #
all - tutte 191.955
article - articoli 190.243
book - libri 0
conference - conferenze 177
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.535
Totale 383.910
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202012.698 0 0 0 0 0 0 3.715 1.361 1.874 3.162 1.964 622
2020/20214.543 323 374 426 442 237 390 201 460 425 531 319 415
2021/20228.214 222 487 428 1.298 191 700 666 1.813 339 720 278 1.072
2022/20237.242 796 308 40 694 1.151 1.571 33 573 1.443 63 477 93
2023/20242.861 193 542 62 277 245 466 138 134 160 53 157 434
2024/20254.256 123 866 363 562 1.350 961 31 0 0 0 0 0
Totale 69.584